Trial supports drugs plus stents approach
This article was originally published in Clinica
Preliminary data from a new trial has backed a previous study which showed that a combination of stents and the platelet receptor blocker abciximab can cut heart attack death rates by half compared with stents alone.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.